An International Survey-based Algorithm for the Pharmacologic Treatment of Chorea in Huntington's Disease

PLoS Currents

Volumn , Issue SEP, 2011, Pages

  Burgunder, Jean Marc ^a,b   Guttman, Mark ^c   Perlman, Susan ^d   Goodman, Nathan ^e   van Kammen, Daniel P ^f   Goodman, LaVonne ^g  

^a UNIVERSITY OF BERN   (Switzerland)

^b SICHUAN UNIVERSITY   (China)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e INSTITUTE FOR SYSTEMS BIOLOGY   (United States)

^f CNS Drug Development consultant   (United States)

^g Huntington's Disease Drug Works   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CLONAZEPAM; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; TETRABENAZINE;

AKATHISIA; ALGORITHM; APATHY; COGNITIVE DEFECT; COMORBIDITY; DEPRESSION; DRUG EFFICACY; DRUG PREFERENCE; DYSPHAGIA; HEALTH SURVEY; HUMAN; HUNTINGTON CHOREA; INJURY; METABOLIC SYNDROME X; MONOTHERAPY; PARKINSONISM; REVIEW; SEDATION; SIDE EFFECT; SLEEP DISORDER; STIGMA; TARDIVE DYSKINESIA; WALKING DIFFICULTY;

EID: 84873416264     PISSN: None     EISSN: 21573999     Source Type: Journal    
DOI: None     Document Type: Review

References (53)

1. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group. Cell. 1993 Mar 26;72(6):971-83. PubMed PMID: 8458085.
2. Wojaczyńska-Stanek K, Adamek D, Marszał E, Hoffman-Zacharska D. Huntington disease in a 9-year-old boy: clinical course and neuropathologic examination. J Child Neurol. 2006 Dec;21(12):1068-73. PubMed PMID: 17156701.
3. Lipe H, Bird T. Late onset Huntington Disease: clinical and genetic characteristics of 34 cases. J Neurol Sci. 2009 Jan 15;276(1-2):159-62. Epub 2008 Oct 31. PubMed PMID: 18977004.
4. Foroud T, Gray J, Ivashina J, Conneally PM. Differences in duration of Huntington's disease based on age at onset. J Neurol Neurosurg Psychiatry. 1999 Jan;66(1):52-6. PubMed PMID: 9886451; PubMed Central PMCID: PMC1736160.
5. "Huntington's Disease" Third Edition Oxford monographs on Medical Genetics, Clinical Neurology of Huntington's disease; Barry Kramer: page 82
6. Tabrizi SJ, Scahill RI, Durr A, Roos RA, Leavitt BR, Jones R, Landwehrmeyer GB, Fox NC, Johnson H, Hicks SL, Kennard C, Craufurd D, Frost C, Langbehn DR, Reilmann R, Stout JC; TRACK-HD Investigators. Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: the 12-month longitudinal analysis. Lancet Neurol. 2011 Jan;10(1):31-42. Epub 2010 Dec 2. PubMed PMID: 21130037.
7. Roos RA. Huntington's disease: a clinical review. Orphanet J Rare Dis. 2010 Dec 20;5(1):40. PubMed PMID: 21171977; PubMed Central PMCID: PMC3022767.
8. Bonelli RM, Wenning GK. Pharmacological management of Huntington's disease: an evidence-based review. Curr Pharm Des. 2006;12(21):2701-20. Review. PubMed PMID: 16842168.
9. Phillips W, Shannon KM, Barker RA. The current clinical management of Huntington's disease. Mov Disord. 2008 Aug 15;23(11):1491-504. Review. PubMed PMID: 18581443.
10. Adam OR, Jankovic J. Symptomatic treatment of Huntington disease. Neurotherapeutics. 2008 Apr;5(2):181-97. Review. PubMed PMID: 18394562.
11. Mestre T, Ferreira J, Coelho MM, Rosa M, Sampaio C. Therapeutic interventions for symptomatic treatment in Huntington's disease. Cochrane Database Syst Rev. 2009 Jul 8;(3):CD006456. Review. PubMed PMID: 19588393.
12. Groves M, van Duijn E, Anderson K, Craufurd D, Edmondson MC, Goodman N, van Kammen DP, Goodman L. An International Survey-based Algorithm for the Pharmacologic Treatment of Irritability in Huntington's Disease. PLoS Curr. 2011 Aug 30;3:RRN1259. PubMed PMID: 21975525.
13. Anderson K, Craufurd D, Edmondson MC, Goodman N, Groves M, van Duijn E, van Kammen DP, Goodman L. An International Survey-based Algorithm for the Pharmacologic Treatment of Obsessive-Compulsive Behaviors in Huntington's Disease. PLoS Curr. 2011 Sep 20;3:RRN1261. PubMed PMID: 21947193; PubMed Central PMCID: PMC3177175.
14. Snowden JS, Craufurd D, Griffiths HL, Neary D. Awareness of involuntary movements in Huntington disease. Arch Neurol. 1998 Jun;55(6):801-5. PubMed PMID: 9626771.
15. Vitale C, Pellecchia MT, Grossi D, Fragassi N, Cuomo T, Di Maio L, Barone P. Unawareness of dyskinesias in Parkinson's and Huntington's diseases. Neurol Sci. 2001 Feb;22(1):105-6. PubMed PMID: 11487181.
16. Hoth KF, Paulsen JS, Moser DJ, Tranel D, Clark LA, Bechara A. Patients with Huntington's disease have impaired awareness of cognitive, emotional, and functional abilities. J Clin Exp Neuropsychol. 2007 May;29(4):365-76. PubMed PMID: 17497560.
17. Bilney B, Morris ME, Perry A. Effectiveness of physiotherapy, occupational therapy, and speech pathology for people with Huntington's disease: a systematic review. Neurorehabil Neural Repair. 2003 Mar;17(1):12-24. Review. PubMed PMID: 12645441.
18. Kim JS, Reading SA, Brashers-Krug T, Calhoun VD, Ross CA, Pearlson GD. Functional MRI study of a serial reaction time task in Huntington's disease. Psychiatry Res. 2004 May 30;131(1):23-30. PubMed PMID: 15246452.
19. Bilney B, Morris ME, Churchyard A, Chiu E, Georgiou-Karistianis N. Evidence for a disorder of locomotor timing in Huntington's disease. Mov Disord. 2005 Jan;20(1):51-7. PubMed PMID: 15390128.
20. Fenney A, Jog MS, Duval C. Bradykinesia is not a "systematic" feature of adult-onset Huntington's disease; implications for basal ganglia pathophysiology. Brain Res. 2008 Feb 8;1193:67-75. Epub 2007 Dec 8. PubMed PMID: 18177845.
21. Sánchez-Pernaute R, Künig G, del Barrio Alba A, de Yébenes JG, Vontobel P, Leenders KL. Bradykinesia in early Huntington's disease. Neurology. 2000 Jan 11;54(1):119-25. PubMed PMID: 10636136.
22. Mahant N, McCusker EA, Byth K, Graham S; Huntington Study Group. Huntington's disease: clinical correlates of disability and progression. Neurology. 2003 Oct 28;61(8):1085-92. PubMed PMID: 14581669.
23. Gonzalez-Alegre P, Afifi AK. Clinical characteristics of childhood-onset (juvenile) Huntington disease: report of 12 patients and review of the literature. J Child Neurol. 2006 Mar;21(3):223-9. PubMed PMID: 16901424.
24. Wheelock VL, Tempkin T, Marder K, Nance M, Myers RH, Zhao H, Kayson E, Orme C, Shoulson I; Huntington Study Group. Predictors of nursing home placement in Huntington disease. Neurology. 2003 Mar 25;60(6):998-1001. PubMed PMID: 12654967.
25. McLellan DL, Chalmers RJ, Johnson RH. A double-blind trial of tetrabenazine, thiopropazate, and placebo in patients with chorea. Lancet. 1974 Jan 26;1(7848):104-7. PubMed PMID: 4130307.
26. Frank S, Marshall F, Plumb S, Oakes D, Shoulson I, Kieburtz K, the CARE-HD Investigators of the Huntington Study Group: Functional decline due to chorea in Huntington's disease. Neurology 2004., 62(suppl 5)
27. Beglinger LJ, O'Rourke JJ, Wang C, Langbehn DR, Duff K, Paulsen JS; Huntington Study Group Investigators. Earliest functional declines in Huntington disease. Psychiatry Res. 2010 Jul 30;178(2):414-8. Epub 2010 May 15. PubMed PMID: 20471695.
28. Grimbergen YA, Knol MJ, Bloem BR, Kremer BP, Roos RA, Munneke M. Falls and gait disturbances in Huntington's disease. Mov Disord. 2008 May 15;23(7):970-6. PubMed PMID: 18381643.
29. Bandstra NF, Camfield CS, Camfield PR. Stigma of epilepsy. Can J Neurol Sci. 2008 Sep;35(4):436-40. Review. PubMed PMID: 18973059.
30. Grytten N, Måseide P. 'When I am together with them I feel more ill.' The stigma of multiple sclerosis experienced in social relationships. Chronic Illn. 2006 Sep;2(3):195-208. PubMed PMID: 17007696.
31. Chapuis S, Ouchchane L, Metz O, Gerbaud L, Durif F. Impact of the motor complications of Parkinson's disease on the quality of life. Mov Disord. 2005 Feb;20(2):224-30. PubMed PMID: 15384126.
32. Davis KK, Davis JS, Dowler L. In motion, out of place: the public space(s) of Tourette Syndrome. Soc Sci Med. 2004 Jul;59(1):103-12. PubMed PMID: 15087147.
33. Schomerus G, Holzinger A, Matschinger H, Lucht M, Angermeyer MC. [Public attitudes towards alcohol dependence]. Psychiatr Prax. 2010 Apr;37(3):111-8. Epub 2010 Feb 10. Review. German. PubMed PMID: 20148378.
34. Rao D, Choi SW, Victorson D, Bode R, Peterman A, Heinemann A, Cella D. Measuring stigma across neurological conditions: the development of the stigma scale for chronic illness (SSCI). Qual Life Res. 2009 Jun;18(5):585-95. Epub 2009 Apr 25. PubMed PMID: 19396572; PubMed Central PMCID: PMC2875076.
35. Erwin C, Williams JK, Juhl AR, Mengeling M, Mills JA, Bombard Y, Hayden MR, Quaid K, Shoulson I, Taylor S, Paulsen JS; I-RESPOND-HD Investigators of the Huntington Study Group. Perception, experience, and response to genetic discrimination in Huntington disease: the international RESPOND-HD study. Am J Med Genet B Neuropsychiatr Genet. 2010 Jul;153B(5):1081-93. PubMed PMID: 20468061.
36. Barr AN, Fischer JH, Koller WC, Spunt AL, Singhal A. Serum haloperidol concentration and choreiform movements in Huntington's disease. Neurology. 1988 Jan;38(1):84-8. PubMed PMID: 2962009.
37. Bonelli RM, Mahnert FA, Niederwieser G. Olanzapine for Huntington's disease: an open label study. Clin Neuropharmacol. 2002 Sep-Oct;25(5):263-5. PubMed PMID: 12410058.
38. Squitieri F, Cannella M, Piorcellini A, Brusa L, Simonelli M, Ruggieri S. Short-term effects of olanzapine in Huntington disease. Neuropsychiatry Neuropsychol Behav Neurol. 2001 Jan;14(1):69-72. PubMed PMID: 11234911.
39. Jiménez-Jiménez FJ, de Toledo M, Puertas I, Barón M, Zurdo M, Barcenilla B. [Olanzapine improves chorea in patients with Huntington's disease]. Rev Neurol. 2002 Sep 16-30;35(6):524-5. Spanish. PubMed PMID: 12389168.
40. Duff K, Beglinger LJ, O'Rourke ME, Nopoulos P, Paulson HL, Paulsen JS. Risperidone and the treatment of psychiatric, motor, and cognitive symptoms in Huntington's disease. Ann Clin Psychiatry. 2008 Jan-Mar;20(1):1-3. PubMed PMID: 18297579.
41. Dallocchio C, Buffa C, Tinelli C, Mazzarello P. Effectiveness of risperidone in Huntington chorea patients. J Clin Psychopharmacol. 1999 Feb;19(1):101-3. PubMed PMID: 9934953.
42. Alpay M, Koroshetz WJ. Quetiapine in the treatment of behavioral disturbances in patients with Huntington's disease. Psychosomatics. 2006 Jan-Feb;47(1):70-2. PubMed PMID: 16384811.
43. Quinn N, Marsden CD. Tiapride in 12 Huntington's disease patients. J Neurol Neurosurg Psychiatry. 1985 Mar;48(3):292. PubMed PMID: 3156967; PubMed Central PMCID: PMC1028279.
44. Deroover J, Baro F, Bourguignon RP, Smets P. Tiapride versus placebo: a double-blind comparative study in the management of Huntington's chorea. Curr Med Res Opin. 1984;9(5):329-38. PubMed PMID: 6241563.
45. van Vugt JP, Siesling S, Vergeer M, van der Velde EA, Roos RA. Clozapine versus placebo in Huntington's disease: a double blind randomised comparative study. J Neurol Neurosurg Psychiatry. 1997 Jul;63(1):35-9. PubMed PMID: 9221965; PubMed Central PMCID: PMC2169648.
46. Brusa L, Orlacchio A, Moschella V, Iani C, Bernardi G, Mercuri NB. Treatment of the symptoms of Huntington's disease: preliminary results comparing aripiprazole and tetrabenazine. Mov Disord. 2009 Jan 15;24(1):126-9. PubMed PMID: 19170197.
47. de Tommaso M, Serpino C, Sciruicchio V. Management of Huntington's disease: role of tetrabenazine. Ther Clin Risk Manag. 2011;7:123-9. Epub 2011 Mar 21. PubMed PMID: 21479143; PubMed Central PMCID: PMC3071349.
48. Huntington Study Group. Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial. Neurology. 2006 Feb 14;66(3):366-72. PubMed PMID: 16476934.
49. Frank S. Tetrabenazine as anti-chorea therapy in Huntington disease: an open-label continuation study. Huntington Study Group/TETRA-HD Investigators. BMC Neurol. 2009 Dec 18;9:62. Erratum in: BMC Neurol. 2011;11:18. PubMed PMID: 20021666; PubMed Central PMCID: PMC2804668.
50. Kenney C, Hunter C, Mejia N, Jankovic J. Is history of depression a contraindication to treatment with tetrabenazine? Clin Neuropharmacol. 2006 Sep-Oct;29(5):259-64. PubMed PMID: 16960470.
51. Peiris JB, Boralessa H, Lionel ND. Clonazepam in the treatment of choreiform activity. Med J Aust. 1976 Feb 21;1(8):225-7. PubMed PMID: 131236.
52. O'Suilleabhain P, Dewey RB Jr. A randomized trial of amantadine in Huntington disease. Arch Neurol. 2003 Jul;60(7):996-8. PubMed PMID: 12873857.
53. Heckmann JM, Legg P, Sklar D, Fine J, Bryer A, Kies B. IV amantadine improves chorea in Huntington's disease: an acute randomized, controlled study. Neurology. 2004 Aug 10;63(3):597-8; author reply 597-8. PubMed PMID: 15304616.